Cargando…

Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights

Purpose: To evaluate the role of sentinel lymph node biopsy (SLNB) in conjunctival melanoma (CM). Methods: This article provides a review of the literature from PUBMED. Results: Data on SLNB in the management of CM are scarce and only two relatively large cohorts have been reported. Although indicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mor, Joel M, Rokohl, Alexander C, Koch, Konrad R, Heindl, Ludwig M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667347/
https://www.ncbi.nlm.nih.gov/pubmed/31440020
http://dx.doi.org/10.2147/OPTH.S187364
_version_ 1783440018219466752
author Mor, Joel M
Rokohl, Alexander C
Koch, Konrad R
Heindl, Ludwig M
author_facet Mor, Joel M
Rokohl, Alexander C
Koch, Konrad R
Heindl, Ludwig M
author_sort Mor, Joel M
collection PubMed
description Purpose: To evaluate the role of sentinel lymph node biopsy (SLNB) in conjunctival melanoma (CM). Methods: This article provides a review of the literature from PUBMED. Results: Data on SLNB in the management of CM are scarce and only two relatively large cohorts have been reported. Although indication criteria for SLNB vary slightly, positive findings can be expected in 11%–13% of CM cases, including small tumors. False negative SLNB findings are rare (<10%). Failure to identify SLNB has been attributed to the surgical learning curve and recurrent tumors with scar tissue impeding spread of the tracer material. Reported 5-year survival rate following CM management including SLNB, is up to 79%, but there are no comparative cohort studies proving the assumed benefit. Adverse events reported were non-severe and transient. Conclusion: Patients can potentially benefit from SLNB and the procedure can be offered to eligible patients. However, there is not enough evidence to support SLNB as a mandatory part of CM management.
format Online
Article
Text
id pubmed-6667347
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66673472019-08-22 Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights Mor, Joel M Rokohl, Alexander C Koch, Konrad R Heindl, Ludwig M Clin Ophthalmol Review Purpose: To evaluate the role of sentinel lymph node biopsy (SLNB) in conjunctival melanoma (CM). Methods: This article provides a review of the literature from PUBMED. Results: Data on SLNB in the management of CM are scarce and only two relatively large cohorts have been reported. Although indication criteria for SLNB vary slightly, positive findings can be expected in 11%–13% of CM cases, including small tumors. False negative SLNB findings are rare (<10%). Failure to identify SLNB has been attributed to the surgical learning curve and recurrent tumors with scar tissue impeding spread of the tracer material. Reported 5-year survival rate following CM management including SLNB, is up to 79%, but there are no comparative cohort studies proving the assumed benefit. Adverse events reported were non-severe and transient. Conclusion: Patients can potentially benefit from SLNB and the procedure can be offered to eligible patients. However, there is not enough evidence to support SLNB as a mandatory part of CM management. Dove 2019-07-23 /pmc/articles/PMC6667347/ /pubmed/31440020 http://dx.doi.org/10.2147/OPTH.S187364 Text en © 2019 Mor et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Mor, Joel M
Rokohl, Alexander C
Koch, Konrad R
Heindl, Ludwig M
Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
title Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
title_full Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
title_fullStr Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
title_full_unstemmed Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
title_short Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
title_sort sentinel lymph node biopsy in the management of conjunctival melanoma: current insights
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667347/
https://www.ncbi.nlm.nih.gov/pubmed/31440020
http://dx.doi.org/10.2147/OPTH.S187364
work_keys_str_mv AT morjoelm sentinellymphnodebiopsyinthemanagementofconjunctivalmelanomacurrentinsights
AT rokohlalexanderc sentinellymphnodebiopsyinthemanagementofconjunctivalmelanomacurrentinsights
AT kochkonradr sentinellymphnodebiopsyinthemanagementofconjunctivalmelanomacurrentinsights
AT heindlludwigm sentinellymphnodebiopsyinthemanagementofconjunctivalmelanomacurrentinsights